Clinical trial
A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors
NCT02939651 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors
- Lead sponsor
- Fox Chase Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 26, 2016
- Completion date
- March 31, 2020
- Enrollment
- 21 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.